Smoking and schizophrenia have a long, complicated relationship. Roughly 60% of people with schizophrenia smoke cigarettes, compared with around 14% of US adults overall — see the CDC tobacco data. There are many reasons for this disparity, but one of them is biological: smoking changes how the liver processes certain antipsychotics, and that change is large enough to matter clinically.
Tobacco smoke induces the liver enzyme CYP1A2, which can lower levels of clozapine and olanzapine by 30 to 50% in heavy smokers — and stopping smoking can sharply raise those levels, sometimes causing toxicity if doses are not adjusted.
What induces what
The CYP1A2 induction comes from polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke — not from nicotine. This is an important distinction. Nicotine replacement therapy, vapes that contain nicotine but not combustion products, and snus do not induce CYP1A2. Only the smoke does. That means a patient who switches from cigarettes to nicotine patches will lose the CYP1A2 induction and behave, pharmacologically, like a non-smoker.
Cannabis smoke contains similar PAHs and can also induce CYP1A2. See our piece on antipsychotics and cannabis.
Drugs most affected
Clozapine
The most clinically important interaction. Heavy smokers can have clozapine levels 30 to 50% lower than otherwise expected. This means smokers often need higher doses to reach the therapeutic plasma level range (often quoted as 350 to 600 ng/mL for response). When a smoker on clozapine quits, levels can rise sharply over one to two weeks. Multiple case reports describe clozapine toxicity — severe sedation, confusion, hypotension, seizures — in patients who stopped smoking without dose adjustment. The Clozaril prescribing information addresses smoking changes explicitly.
Most clozapine clinics now recommend checking plasma levels within one to two weeks of smoking cessation and adjusting the dose downward if needed — sometimes by as much as 30 to 40%.
Olanzapine
Olanzapine is also a CYP1A2 substrate, with similar (though usually less dramatic) effects. The Zyprexa label notes that smokers may have lower olanzapine clearance compared with non-smokers and that dose adjustments may be needed when smoking status changes.
Other agents
- Asenapine — minor CYP1A2 substrate; smoking has a smaller effect
- Haloperidol — partly CYP1A2; modest effect, occasional clinical relevance
- Chlorpromazine — partly CYP1A2; effect is modest
- Fluphenazine — minor CYP1A2 metabolism
Most second-generation agents — risperidone, paliperidone, quetiapine, aripiprazole, lurasidone, lumateperone, cariprazine — are not significantly affected by smoking and do not require dose changes.
What changes when you quit
Within about a week of stopping tobacco smoke, CYP1A2 activity begins returning to baseline. By two to four weeks, the change is largely complete. For clozapine, this means that a patient on a stable dose of 500 mg per day might effectively be receiving the equivalent of 700 mg per day after quitting, without anyone changing the prescription.
The clinical implications:
- Plan smoking cessation in coordination with your prescriber
- Plasma levels are useful — particularly for clozapine
- Watch for new sedation, drooling, constipation, dizziness on standing, or seizures
- Dose reductions are often needed within the first one to two weeks
Cessation matters more than the interaction
Despite the pharmacological complications, smoking cessation is one of the highest-impact health interventions in schizophrenia. People with schizophrenia die younger than the general population by 10 to 25 years, mostly from cardiovascular disease, COPD, and lung cancer — much of it driven by smoking. The CYP1A2 issue is real but is a manageable problem of monitoring, not a reason to keep smoking. See schizophrenia and smoking cessation.
Effective cessation tools include:
- Nicotine replacement therapy (patches, gum, lozenge)
- Varenicline (Chantix) — multiple trials, including the EAGLES trial summarised by the FDA, support efficacy and safety in serious mental illness
- Bupropion (Zyban) — useful for some, with caution about seizure threshold and interactions
- Behavioural support, including the 1-800-QUIT-NOW network
You develop new severe sedation, confusion, drooling, slow heart rate, or a seizure in the weeks after quitting smoking on clozapine — these can be signs of clozapine toxicity from rising drug levels.
Practical questions to ask your prescriber or pharmacist
- Am I on a CYP1A2-metabolised antipsychotic?
- If I plan to quit smoking, when should we check drug levels and how often?
- Should we lower my dose preemptively, or wait for level results?
- Will switching from cigarettes to nicotine patches still cause level changes? (Yes — patches do not induce CYP1A2.)
- Is there a different antipsychotic with a similar profile that is not affected by smoking?
The bottom line
Smoking is one of the most potent and predictable drug interactions in psychiatry — and it is fully reversible when you quit. For clozapine and olanzapine in particular, both starting and stopping smoking should happen in coordination with a prescriber who understands the pharmacology. The interaction is not a reason to keep smoking; it is a reason to quit deliberately, with monitoring, and with your treatment team in the loop.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.